[Comment] A novel unimolecular GLP1 and amylin receptor agonist for glucose and weight control | ClinicLens
The therapeutic landscape of type 2 diabetes and obesity has evolved from single-hormone incretin modulation towards multireceptor metabolic engineering. Amylin is cosecreted with insulin from pancreatic β cells in response to food intake and acts on amylin receptors distributed
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.